Arcus Biosciences, Inc. Increase (Decrease) in Deferred Revenue
Arcus Biosciences, Inc. (RCUS) reported Increase (Decrease) in Deferred Revenue of -$2.00 million for the 12-month period ending 2019-12-31, per its 10-K filed 2020-03-05.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInDeferredRevenue · last filed 2020-03-05
- Arcus Biosciences, Inc. increase (decrease) in deferred revenue for the quarter ending 2018-12-31 was -$1.56M.
- Arcus Biosciences, Inc. increase (decrease) in deferred revenue for the quarter ending 2018-09-30 was $3.71M.
- Arcus Biosciences, Inc. increase (decrease) in deferred revenue for the quarter ending 2018-06-30 was -$1.25M.
- Arcus Biosciences, Inc. increase (decrease) in deferred revenue for the quarter ending 2018-03-31 was -$1.25M.
- Arcus Biosciences, Inc. increase (decrease) in deferred revenue for fiscal 2019 was -$2.00M.
- Arcus Biosciences, Inc. increase (decrease) in deferred revenue for fiscal 2018 was -$353.00K, a 101.50% decline from fiscal 2017.
- Arcus Biosciences, Inc. increase (decrease) in deferred revenue for fiscal 2017 was $23.59M.
- Arcus Biosciences, Inc. increase (decrease) in deferred revenue for fiscal 2016 was $0.00.
| Period end | Increase (Decrease) in Deferred Revenue 3 month | Increase (Decrease) in Deferred Revenue 6 month | Increase (Decrease) in Deferred Revenue 9 month | Increase (Decrease) in Deferred Revenue 12 month |
|---|---|---|---|---|
| 2019-12-31 | -$2.00M 10-K · filed 2020-03-05 | |||
| 2018-12-31 | -$1.56M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-05 | $2.15M derived: sum of 2 quarters · filed 2020-03-05 | $897.00K derived: sum of 3 quarters · filed 2020-03-05 | -$353.00K 10-K · filed 2020-03-05 |
| 2018-09-30 | $3.71M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-08 | $2.46M derived: sum of 2 quarters · filed 2018-11-08 | $1.21M 10-Q · filed 2018-11-08 | -$41.00K derived: sum of 4 quarters · filed 2019-03-05 |
| 2018-06-30 | -$1.25M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-06 | -$2.50M 10-Q · filed 2018-08-06 | -$3.75M derived: sum of 3 quarters · filed 2019-03-05 | |
| 2018-03-31 | -$1.25M 10-Q · filed 2018-05-09 | -$2.50M derived: sum of 2 quarters · filed 2019-03-05 | ||
| 2017-12-31 | -$1.25M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-05 | $23.59M 10-K · filed 2019-03-05 | ||
| 2017-09-30 | $24.84M 10-Q · filed 2018-11-08 | |||
| 2016-12-31 | $0.00 10-K · filed 2019-03-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |